ZURA · Zura Bio
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $1.70
Note written ·
Price against the kill line
27.1% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $1.70, on record since 11 November 2026. The shares are down 78.2% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $1.70, a level the shares last held on 6 November 2026 before the trial failure (they closed at $4.09), which would show the shares leading again. A positive primary-endpoint result in the TibuSURE systemic sclerosis study would also prove the call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 27 October 2026
- Net cash, cash less debt ($M)
- 188
All filed numbers
What Zura Bio reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | −27.0 |
| Net income ($M) four quarters: −93.5 | −25.8 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +35.1 |
| Operating cash flow ($M) | Not available |
| Capital spending ($M) | Not available |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 188 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 188 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) including non-controlling interests | 178 |
| Market value ($M) | 119 |
| Enterprise value, market value plus net debt ($M) no debt reported | −68.2 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 0.7 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 7.3% of shares outstanding sold short, 1.5 days of average trading to cover, −25.1% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $12.5M | $0 |
The thesis
Zura Bio's shares are more likely to lag the S&P 500 over the next three months. The Phase 2 TibuSHIELD study of tibulizumab in hidradenitis suppurativa (HS), an inflammatory skin disease, missed its primary and key secondary endpoints on 9 November 2026, and the company is discontinuing development in that indication. What remains is the TibuSURE study in systemic sclerosis, guided to report in the first half of 2027, and that result settles whether the company has a clinical case left.
The shares closed at $4.09 on 6 November 2026 and at $1.24 on 9 November 2026, the 52-week closing low, and closed at $1.24 again on 12 November 2026. The three-month change is −77.7%, measured from the $5.57 close on 14 August 2026. Zura filed an 8-K ("other events") on 9 November 2026, the day of the announcement.
The rating is Low because the main asset has failed, the next clinical result is at least five months away, and a $700 million securities filing dated 27 October 2026 leaves share issuance possible. Cash is the counterweight: $187.7 million at 30 September 2026, with management projecting funding through at least the end of 2028.
Bullish and bearish views on Zura Bio Limited
The bull case on Zura Bio Limited (ZURA), in brief: cash remains large. The bear case: the lead indication failed.
Bull case
- Cash remains large. Cash and equivalents were $187.7 million at 30 September 2026, and the company's Q3 release projects funding of planned operations through at least the end of 2028. The balance sheet showed 96.3 million shares outstanding at that date.
- A second study is still running. TibuSURE in systemic sclerosis randomized 91 participants and is guided to report topline data in the first half of 2027, per the company's 27 October 2026 release. Panabee, summarising the 9 November 2026 announcement, reports that the company remains committed to it.
- Safety did not stop the drug. Panabee, summarising the company's 9 November 2026 release, reports discontinuations from adverse events of 2.4% (300 mg), 3.7% (150 mg) and 2.4% (placebo), and a profile consistent with blocking interleukin-17 and B-cell activating factor (BAFF). The miss was one of efficacy.
- Analysts kept positive ratings. Wedbush maintained Outperform with a $10 target (9 November 2026). Guggenheim maintained Buy with an $8 target (10 November 2026). Oppenheimer maintained Outperform and cut its target to $5 (10 November 2026). All three targets are well above the $1.24 close of 12 November 2026.
Bear case
- The lead indication failed. Per Panabee, the mean reduction in abscess and inflammatory nodule count at Week 16 was 56.0% on 300 mg and 58.1% on 150 mg, against 52.5% on placebo. The study randomized 247 participants, and the HiSCR50 and HiSCR75 secondary measures were also missed.
- The next test is far away. TibuSURE reports no earlier than the first half of 2027. Panabee reports that data from the polymyalgia rheumatica study, NEXUS-PMR, are not expected until the fourth quarter of 2028, which is after the guided cash runway.
- Spending continues without a lead program. The third-quarter 2026 net loss was $25.8 million, or $0.20 per share, per the company's 27 October 2026 release. Research and development expense was $19.5 million, up from $11.9 million a year earlier.
- Supply risk is on file. Zura filed a prospectus on 27 October 2026 for up to $700 million of securities. An at-the-market sales agreement with Leerink Partners had $114.0 million available at 31 March 2026, per the first-quarter 10-Q.
- Legal and strategic overhang. A shareholder investigation of the trial results was announced on 11 November 2026. Panabee-cited commentary frames the open question as whether the remaining programs justify spending or the board turns to strategic alternatives. No formal review has been reported.
Price setup
ZURA closed at $4.09 on 6 November 2026, $1.24 on 9 November 2026, $1.41 on 10 November 2026, $1.43 on 11 November 2026 and $1.24 on 12 November 2026. The 52-week closing low is $1.24, set on 9 November 2026. The 52-week intraday high is $7.44, set on 10 March 2026.
The 50-day average of adjusted closes is $4.11 and the 200-day average is $5.10, both as of 12 November 2026. Both sit far above the last close because they still include sessions before the failure. The $1.43 close on 11 November 2026 is the highest post-announcement close. A rebound inside the new range does not change the clinical position until TibuSURE reports.
The price already reflects the loss of the hidradenitis suppurativa program: the shares fell from $4.09 to $1.24 across the 9 November 2026 session. Whether $187.7 million of cash at 30 September 2026 is worth more than the remaining pipeline depends on cash burn and any move on the $700 million filing. No SEC Form 4 insider transactions appear among the company's recent filings.
Catalysts ahead
- 31 December 2026: Company target to start the NEXUS-PMR Phase 2 study of tibulizumab in polymyalgia rheumatica by year-end 2026. Shows whether Zura keeps its remaining development plan on schedule after dropping hidradenitis suppurativa.
- ~30 June 2027 (est.): End of the first half of 2027, the guided window for TibuSURE topline data in systemic sclerosis. This is the next clinical result for tibulizumab and decides whether the company has a lead program left.
What would change the view
A daily close above $1.70, a level the shares last held on 6 November 2026 before the trial failure (they closed at $4.09), which would show the shares leading again. A positive primary-endpoint result in the TibuSURE systemic sclerosis study would also prove the call wrong.
What it trades with
ZURA trades on its own trial results and balance sheet, not on a sector trend. Read-across runs to other programs targeting interleukin-17 and B-cell pathways. The HS result shows how high the placebo response can be in HS trials, a point Panabee raises about the field. Small-cap biotech funding conditions affect the cost of any offering under the $700 million filing. Shares of cash-rich, post-failure biotechs can trade on balance-sheet questions as much as on pipeline news.
The evidence, claim by claim (8)
- Zura said Phase 2 TibuSHIELD of tibulizumab in hidradenitis suppurativa missed its primary and key secondary endpoints; the company is discontinuing development in that indication. Zura Bio 8-K, 9 November 2026; Fierce Biotech, 9 November 2026 · as of
- Week 16 reduction in abscess and inflammatory nodule count was 56.0% (300 mg), 58.1% (150 mg) and 52.5% (placebo) among 247 randomized participants. Panabee summary of Zura Bio 9 November 2026 announcement · as of
- Cash and equivalents were $187.7 million at 30 September 2026; management projects funding of planned operations through at least the end of 2028. Zura Bio third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Third-quarter 2026 net loss was $25.8 million, or $0.20 per share; research and development expense was $19.5 million, up from $11.9 million a year earlier. Zura Bio third-quarter 2026 results release · as of
- The shares closed at $4.09 on 6 November 2026 and $1.24 on 9 November 2026, the 52-week closing low; the close on 12 November 2026 was $1.24. Split-adjusted daily closes · as of
- Wedbush kept Outperform with a $10 target (9 November 2026); Guggenheim kept Buy with an $8 target and Oppenheimer kept Outperform with a $5 target (both 10 November 2026). Analyst rating headlines, 9 November 2026 and 10 November 2026 · as of
- Zura filed a prospectus for up to $700 million of securities. Form S-3 dated 27 October 2026 · as of
- A shareholder investigation of Zura Bio following the clinical trial results was announced. Company news headline, 11 November 2026 · as of
Sources
Related · shared themes
IRON
Disc Medicine
Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19…
MANE
Veradermics
Veradermics' hair-loss pill VDPHL01 has finished its male trials with clean 12-month safety and cash of $798.4M guided into 2030. The case…
SMMT
Summit Therapeutics
Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's…
ZLAB
Zai Lab
Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line…